Navigation Links
Investment in Oncology Drug Development Remains Strong as 133 Companies Initiate Late-Stage Clinical Trials Representing a 21% Increase
Date:6/2/2011

NEW YORK, June 2, 2011 /PRNewswire/ -- Citeline, the world's leading research authority on pharmaceutical clinical trials and intelligence recently completed a comprehensive review of clinical trial starts in the oncology therapeutic area to uncover trends and patterns in drug development. Over the one-year review period (October 2009 through September 2010) over 400 late stage trials were initiated in the oncology sector, more than any other therapeutic area, according to Citeline analysts.

(Photo: http://photos.prnewswire.com/prnh/20110602/NE12798 )

Non-small cell lung cancer was the leading disease type, followed closely by breast cancer.  "Notably, trials enrolling multiple hematological cancers and multiple solid tumors came in third and sixth, respectively, among all oncology diseases," commented Dr. Fern Barkalow, Oncology Senior Analyst at Citeline. "These trials represented 10% of the total, which was almost double that of the prior year, suggesting an effort by industry to increase the likelihood of success."

Additional highlights from the Citeline analysis include the following:

  • Hodgkin's lymphoma and supportive care were the only indications that had more Phase III than Phase II trial starts.  
  • Both Merck KGaA and Boehringer Ingelheim had the highest proportions of Phase III to Phase II trial starts.
  • The majority of the trials initiated by the leading five companies evaluated targeted therapies, ranging from 63% to 97% of their trial starts.

Sector sees new entrants

The high level of activity in the oncology therapeutic area was further underlined by the significant number (133) of distinct companies sponsoring new trials in the 12-month period. This represents a 21% increase over the previous year.  Coincident with the increase in the number of sponsors, was a sm
'/>"/>

SOURCE Citeline
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Bacterin International Receives $1 million Initial Investment of $31 Million Purchase Agreement with Lincoln Park Capital Fund, LLC
2. Reportlinker Adds Greece Drug Delivery Devices Investment Opportunities, Analysis and Forecasts to 2017
3. Reportlinker Adds United Arab Emirates Neurology Devices Investment Opportunities, Analysis and Forecasts to 2017
4. TetraLogic Closes $6 Million Series C-1 Investment with Nextech Invest Ltd.
5. CVS Caremark to Participate in the Citi Investment Research 2011 Global Consumer Conference
6. Varian Medical Systems Makes Equity Investment and Obtains Option to Purchase Augmenix
7. SC Launch Presents "Big Check" Investment to Two South Carolina Companies
8. Cadence Pharmaceuticals CEO Ted Schroeder to Present at Three Investment Conferences During the Month of May 2011
9. Reportlinker Adds Medical Equipment Monthly Deals Analysis - M&A and Investment Trends, April 2011
10. MEDomics Announces a Growth Capital Investment from SpaGus Ventures LLC and Gary Augusta Joins MEDomics as Chief Operating Officer
11. Mindray Medical to Present at the 14th Annual Credit Suisse Asian Investment Conference on March 21-25
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)...   AcelRx Pharmaceuticals, Inc.  (Nasdaq: ACRX ... and commercialization of innovative therapies for the treatment of ... for Zalviso remains July 27, 2014.  The ... the Food and Drug Administration (FDA) had approved Zalviso.  ... notification to the company from the FDA regarding the ...
(Date:7/24/2014)... PLAINFIELD, N.J. , July 24, 2014  PTC ... that the Company will host a webcast conference call ... provide an update on the company,s business and outlook ... before the opening of the market. ... (domestic) or (973) 935-8152 (international) five minutes prior to ...
(Date:7/24/2014)... , Deutschland, und MARSEILLE ... -- , Weltweite ... ermöglicht QIAGEN die Entwicklung von Tests ... für Blutkrebs  Neuer Test weist ... mit Knochenmarkserkrankungen (myelodysplastischen Syndromen) einen günstigen Krankheitsverlauf ...
Breaking Medicine Technology:AcelRx Pharmaceuticals Confirms July 27, 2014 PDUFA Date for Zalviso 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 2QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 3QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 4QIAGEN erweitert Pipeline für die personalisierte Medizin um vielversprechende genomische Biomarker zur Prognosebestimmung bei Blutkrebsbehandlungen 5
(Date:7/25/2014)... Florida Hospital and MOSI officially announced a transformational ... to come and make a difference in the Tampa Bay ... check to provide the support needed to keep the science ... transform the IMAX Dome Theatre from film to a state-of-the-art ... Dome Theatre in the state of Florida, and it is ...
(Date:7/25/2014)... -- The human brain can preserve oxygen to protect ... finds. Although dehydration significantly reduces blood flow ... the brain compensates by increasing the amount of oxygen ... helped us understand a lot more about how the ... study first author Steven Trangmar, a researcher at Brunel ...
(Date:7/25/2014)... 25, 2014 AttorneyOne.com, a recognized authority on ... from the FDA on Ibuprofen and Oxcarbazepine Tablets . ... lot of Ibuprofen and one lot of Oxcarbazepine Tablets, by ... mislabeled packaging. Oxcarbazepine is used for the treatment of certain ... The reason for the recall is that Lot #142588, Expiration ...
(Date:7/25/2014)... (PRWEB) July 25, 2014 A new study ... revealed that 39 percent of all children in the survey ... , The survey looked at 2,505 children during the years of ... four years of age. The final result was that about ... care. Many of these children were from lower-income families and were ...
(Date:7/25/2014)... 25, 2014 A new study of participants ... which are published today in Cancer , found evidence ... 74 who had an abnormal finding on a lung cancer ... of life than did those who were screened and found ... surprise to the researchers. “We expected that participants with an ...
Breaking Medicine News(10 mins):Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 2Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 3Health News:Florida Hospital Donates a Two Million Dollar Transformational Gift to the Museum of Science and Industry (MOSI) 4Health News:Human Brain Has Coping Mechanism for Dehydration 2Health News:Ibuprofen and Oxcarbazepine Tablets Recalled: AttorneyOne Monitors and Keep Consumers Informed 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 2Health News:North York Dental Provides Services to Toronto Children in Light of Growing Demand 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 2Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 3Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 4Health News:Full Explanation Reduces Seniors’ Worries about Lung Cancer Screening 5
... http://www.cryocath.com , Toronto Stock Exchange Symbol: CYT, ... leader in cryotherapy products to treat cardiac,arrhythmias, today announced ... Selected Third Quarter Financial and Operational Highlights: ... $9.2 million or a 12.0% increase over ...
... NANJING, China, Aug. 5 /Xinhua-PRNewswire/ -- Simcere Pharmaceutical,Group (NYSE: ... branded generic,pharmaceuticals and manufacturer of the patented anti-cancer biotech,product ... the,quarter ended June 30, 2008., Highlights ... for the second quarter, representing ...
... Mass., Aug. 5 Indevus,Pharmaceuticals, Inc. (Nasdaq: IDEV ... third quarter ended June 30, 2008. The,Company will host ... am,eastern time (details follow below)., The Company reported ... $19.0 million or $0.25 per share for the quarter ...
... IRVINE, Calif., Aug. 5 SectorWatch.biz announces the,availability ... release of,articles and message boards relative to the ... aforementioned equities and the,opportunity for investors to respond ... can view MarketStats by visiting: http://www.SectorWatch.biz ,-a ...
... Goodison goes for gold and aims to give back to Mercy Ships ... ... European Laser Champion and one of Britain,s greatest medal hopes at the ... seagoing charity Mercy Ships which provides free medical care to the people ...
... age management practice, announced the opening of Cenegenics Indiana. ... leader is launching over 2008-2009. The new Cenegenics Indiana ... The center,s established protocols and personalized programs for healthy ... Minutes, 20/20, Nightline and GQ. , ...
Cached Medicine News:Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 2Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 3Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 4Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 5Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 6Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 7Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 8Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 9Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 10Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 11Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 12Health News:CryoCath Announces Fiscal 2008 Third Quarter Results 13Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 2Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 3Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 4Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 5Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 6Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 7Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 8Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 9Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 10Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 11Health News:Simcere Pharmaceutical Group Reports Unaudited Second Quarter 2008 Results 12Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 2Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 3Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 4Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 5Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 6Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 7Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 8Health News:Indevus Pharmaceuticals Announces Third Quarter Fiscal 2008 Financial Results 9Health News:SectorWatch.biz Issues MarketStats for Healthy and Organic Companies ORGC, DF, WFMI, LWAY, COIN, and TOF 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 2Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 3Health News:Olympic Sailing Hopeful Backs Hospital Ship Charity 4
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
Medicine Products: